ImmunoGen, Inc. - Common Stock (NQ:IMGN)

N/A UNCHANGED

Last Price Updated: 4:00 PM EST, Feb 9, 2024 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about ImmunoGen, Inc. - Common Stock

< Previous 1 2

...

6 7 8 9 10 11 12 13 Next >

ImmunoGen Presents Findings from Expansion Cohorts in Phase 1b/2 Study of Pivekimab Sunirine with Vidaza® and Venclexta® in Acute Myeloid Leukemia at ASH

December 10, 2022

From ImmunoGen, Inc.

Via Business Wire

ImmunoGen Announces Clinical Collaboration with Gilead to Evaluate Pivekimab Sunirine in Combination with Magrolimab in Relapsed/Refractory Acute Myeloid Leukemia

December 09, 2022

From ImmunoGen, Inc.

Via Business Wire

Mirati Plays Catch-Up With Amgen, Gilead's 2nd Try With AIDS Drug, Cytokinetics' Adcom Test And More: Key Nov FDA Decisions For Biotech Investors ↗

December 02, 2022

Food and Drug Administration decisions and advisory committee verdicts slated for November were mostly positive. New molecular entity approvals so far this year trail 2021’s tally by about 35%.

Via Benzinga

Looking Into Immunogen's Return On Capital Employed ↗

November 28, 2022

Via Benzinga

After FDA Approval For Ovarian Cancer Drug, ImmunoGen Becomes Top Pick For This Analyst ↗

November 16, 2022

Via Benzinga

ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

December 01, 2022

From ImmunoGen, Inc.

Via Business Wire

Research and Development of Advanced Therapeutics for Ovarian Cancer Fueling Hope

December 01, 2022

EQNX::TICKER_START (OTCQB:BVAXF),(NASDAQ:CTIC),(NASDAQ:SGEN),(NYSE:MRK),(NASDAQ:IMGN) EQNX::TICKER_END

Via FinancialNewsMedia

Topics Intellectual Property

Expert Ratings for Immunogen ↗

November 16, 2022

Via Benzinga

Why Jim Cramer Sees 'Another Bad Quarter Ahead' For Ford, And What Will Turn Things Around ↗

November 23, 2022

On CNBC’s "Mad Money Lightning Round," Jim Cramer said Vista Outdoor Inc (NYSE: VSTO) can be "bought here. I would not push it, though."

Via Benzinga

ImmunoGen Appoints Daniel Char as Senior Vice President and Chief Legal Officer

November 21, 2022

From ImmunoGen, Inc.

Via Business Wire

Vodafone, Getty Images Holdings, Haynes International And Some Other Big Stocks Moving Lower On Tuesday ↗

November 15, 2022

U.S. stocks traded higher, with the Nasdaq gaining more than 200 points on Tuesday. Here are some big stocks recording losses in today’s session.

Via Benzinga

PDS Biotechnology To Rally Around 129%? Here Are 5 Other Price Target Changes For Tuesday ↗

November 15, 2022

Via Benzinga

Why Fast Radius Shares Plunged Around 48%; Here Are 103 Biggest Movers From Yesterday ↗

November 16, 2022

Gainers Satixfy Communications Ltd. (NYSE: SATX) shares gained 140.7% to settle at $31.80 on Tuesday.

Via Benzinga

HUYA, Tencent Music Entertainment, Taiwan Semiconductor Manufacturing, And Some Other Big Stocks Moving Higher In Today's Pre-Market Session ↗

November 15, 2022

U.S. stock futures traded higher this morning. Here are some big stocks recording gains in today’s pre-market trading session.

Via Benzinga

FDA Grants Conditional Approval To First Antibody Drug Conjugate From ImmunoGen For Pretreated Ovarian Cancer ↗

November 15, 2022

Via Benzinga

ImmunoGen Announces FDA Accelerated Approval of ELAHERE™ (mirvetuximab soravtansine-gynx) for the Treatment of Platinum-Resistant Ovarian Cancer

November 14, 2022

From ImmunoGen Inc.

Via Business Wire

Recap: Immunogen Q3 Earnings ↗

November 04, 2022

Immunogen (NASDAQ:IMGN) reported its Q3 earnings results on Friday, November 4, 2022 at 06:30 AM. Here's what investors need to know about the announcement. Earnings Immunogen missed estimated earnings...

Via Benzinga

ImmunoGen Reports Recent Progress and Third Quarter 2022 Financial Results

November 04, 2022

From ImmunoGen, Inc.

Via Business Wire

Preview: Immunogen's Earnings ↗

November 03, 2022

Immunogen (NASDAQ:IMGN) is set to give its latest quarterly earnings report on Friday, 2022-11-04. Here's what investors need to know before the announcement. Analysts estimate that Immunogen will...

Via Benzinga

ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

November 01, 2022

From ImmunoGen, Inc.

Via Business Wire

Earnings Scheduled For November 4, 2022 ↗

November 04, 2022

Companies Reporting Before The Bell • Sprott (NYSE:SII) is likely to report quarterly earnings at $0.49 per share on revenue of $49.95 million. • Telefonica (NYSE:TEF) is likely to report earnings for...

Via Benzinga

Provention Bio's Second Try, Apellis's Eye Disorder Drug Review, 3 Adcom Verdicts And More: November's Key PDUFA Catalysts Biotech Investors Must Know ↗

November 01, 2022

October proved to be a mixed month for the Food and Drug Administration’s regulatory decisions. Two new molecular entities, or NMEs, were approved during the month, bringing the tally for the...

Via Benzinga

ImmunoGen Announces Departure of Chief Commercial Officer

November 01, 2022

From ImmunoGen, Inc.

Via Business Wire

ImmunoGen Presents Retrospective Analysis of Extended Treatment Benefit from Multiple Trials of Mirvetuximab Soravtansine in Ovarian Cancer at ESGO

October 28, 2022

From ImmunoGen, Inc.

Via Business Wire

ImmunoGen Announces Conference Call to Discuss Its Third Quarter 2022 Operating Results

October 20, 2022

From ImmunoGen Inc.

Via Business Wire

ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

October 03, 2022

From ImmunoGen, Inc.

Via Business Wire

ImmunoGen Presents Comprehensive Updates for Mirvetuximab Soravtansine Combination Data in Ovarian Cancer at IGCS

September 29, 2022

From ImmunoGen, Inc.

Via Business Wire

ImmunoGen Announces Webcast of Presentation and Q&A at Upcoming Guggenheim Nantucket Therapeutics Conference

September 14, 2022

From ImmunoGen, Inc.

Via Business Wire

ImmunoGen Presents Additional Analyses Evaluating Mirvetuximab Soravtansine in Ovarian Cancer at ESMO

September 11, 2022

From ImmunoGen, Inc.

Via Business Wire

Benzinga's Top Ratings Upgrades, Downgrades For September 9, 2022 ↗

September 09, 2022

Upgrades

Via Benzinga

< Previous 1 2

...

6 7 8 9 10 11 12 13 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.